Lupin’s wholly owned subsidiary -- Lupin Digital Health has launched VITALYFE, an AI-powered cardiometabolic wellness platform designed to help India’s working professionals reclaim their heart health. Built on the foundation of LYFE - India’s first CDSCO-approved Class C software medical device (SaMD) for critical cardiac conditions - VITALYFE extends hospital-grade cardiac expertise to preventive wellness for its users.
Developed with industry-leading cardiometabolic expertise, VITALYFE uses artificial intelligence, behavioral science, and computer-vision technology to identify early risks and provide personalized, non-medical interventions that address the root causes of heart aging. Available exclusively through insurers, brokers, and employers, the platform enables organizations to integrate cardiometabolic wellness into their health benefits - improving productivity, engagement, and overall well-being while helping insurers reduce lifestyle-related claims.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
